Background. Hepatitis C virus (HCV) is associated with various glomerulopathies, in which HCV is responsible not only for the onset of glomerulopathy but also for its progressive loss of kidney function. The effect of antiviral treatment on the glomerular lesions and subsequent course of kidney disease remains controversial. Therefore, we performed a systematic analysis of the available evidence on the effect of interferon (IFN)-a-based therapy on HCVassociated chronic kidney disease. Methods. A meta-analysis was performed of controlled and uncontrolled clinical studies related to IFNa-based antiviral therapy and its impact on kidney function in HCV-associated glomerulonephritis. Improvement of proteinuria and serum creatinine levels after antiviral therapy was taken as the end points of interest. Data from eligible studies selected according to protocols were analysed using Review Manager 5.0. Results. Eleven clinical trials involving 225 patients were included in our meta-analysis. At the end of antiviral therapy, the summary estimate of the mean decrease in proteinuria was 2.71 g/24 h [95% confidence interval (CI) 1.38-4.04, P < 0.0001], P-value for heterogeneity 0.05 (I 2 ¼ 53%). The pooled decrease in mean serum creatinine levels was 0.23 mg/dL (95% CI 0.02-0.44, P ¼ 0.03), P-value for heterogeneity 0.30 (I 2 ¼ 17%). Comparison of nonsustained virological response (SVR) to SVR groups demonstrated a mean difference of proteinuria decrease in the SVR group of 1.04 g/24 h (95% CI 0.20-1.89, P ¼ 0.02), P-value for heterogeneity 0.21 (I 2 ¼ 36%) and of serum creatinine decrease of 0.05 mg/dL (95% CI À0.33 to 0.43, P ¼ 0.80), P-value for heterogeneity 0.70 (I 2 ¼ 0%). Conclusions. Antiviral therapy based on IFNa can significantly decrease proteinuria and stabilize serum creatitine, and therefore, should be undertaken in patients with HCVassociated glomerulonephritis. The improvement in protein excretion is greater in those who achieve HCV RNA clearance, a finding in line with a causal role for HCV in glomerulonephritis.
Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the world. The World Health Organization estimates that there are 170 million individuals with HCV infection and an incidence of 3-4 million new cases per year [1] . HCV infection is often associated with a number of extrahepatic disorders, including cryglobulinemia, glomerulonephritis, porphyria cutanea tarda, lichen planus, seronegative arthritis, type 2 diabetes mellitus and lymphoproliferative disorders [2] . An increasing number of reports show that chronic HCV infection is associated with various glomerulopathies such as membranoproliferative glomerulonephritis (MPGN), membranous glomerulonephritis, mesangioproliferative glomerulonephritis and focal and segmental glomerulosclerosis [3] [4] [5] , among which MPGN, with or without cryglobulinemia, is the most common type of glomerulopathy [6] .
The renal lesions associated with HCV are attributed to injury due to cryoglobulins and deposition of circulating immune complexes containing HCV and its antibodies [7, 8] . HCV RNA has been detected in the serum of most and in the renal parenchyma of some of these patients [9] . The clinical manifestations of the glomerulopathy range from isolated proteinuria to overt nephritic (20-30%) or nephrotic syndrome (20%), with variable degrees of progressive loss of kidney function [3, 10] . Positive anti-HCV serologic status has further been associated with an increased occurrence of infections [11] , diabetes mellitus [12] and de novo or recurrent glomerulopathy in kidney transplant recipients [13] . As such, the treatment of patients with chronic kidney diseases (CKD) who are infected with HCV should be undertaken before they progress to end-stage renal disease (ESRD) or require kidney transplantation [14] .
HCV-related liver disease can be treated successfully with antiviral therapy, along with eradication of HCV infection [15] . However, the role of antiviral treatment in HCV-associated glomerulonephritis has been controversial. The kidney plays a role in the catabolism and clearance of both interferon (IFN)-a and ribavirin, and thus their clearance is altered in patients with reduced kidney function [15] , and these patients are subject to an increased incidence and severity of side effects of both drugs. Additionally, the virological response and patient dropout rates with antiviral therapy are~40% and 20-30%, respectively [16] . As a result, although several studies of antiviral treatment of hepatitis C in CKD patients have been reported, the majority of them are uncontrolled studies and generally include a small number of studied subjects. Non-responses or relapses after IFNa discontinuation are frequent [6] , although some anecdotal studies report complete remission in cases treated with IFNa alone or combined with ribavirin [12, [17] [18] [19] . Some reports suggest that IFNa therapy was not useful or even harmful during the acute phase of kidney disease [20, 21] , while others report a good response during the stationary phase of the disease [22, 23] .
The primary goal of our study was to synthesize the available evidence by a systematic analysis of the effect of antiviral therapy on HCV-associated CKD based on a meta-analysis of controlled and uncontrolled studies.
Subjects and methods

Criteria for inclusion
Studies included in this meta-analysis had to fulfil a set of criteria. They had to be published in a peer-reviewed journal as a full paper. Controlled or uncontrolled studies on CKD patients receiving antiviral therapy based on IFNa were included. HCV infection was defined by positive testing for anti-HCV antibody and HCV RNA in serum. Studies which included ESRD patients on maintenance dialysis (hemo-or peritoneal dialysis), and kidney transplant recipients were excluded. Studies were excluded if they reported inadequate data on response to antiviral therapy or were only published as abstracts or interim reports. Studies enrolling individuals with positive serology for HBsAg or antibodies to HIV were excluded. The decision to include or exclude a study was made independently of its outcome.
End points of interest
The primary outcome of interest was the level of proteinuria at the end of therapy or during follow-up. The secondary outcome was the improvement in serum creatinine level at the end of therapy and follow-up.
Data sources and search strategy
Electronic searches of MEDLINE database and Embase, and manual searches of selected specialty journals were performed to identify the pertinent literature. The keywords 'Hepatitis C Virus', 'Interferon', 'Chronic kidney Disease' and their synonyms or related terms were used. Reference lists from qualitative topic reviews and published clinical trials were also searched. The search was limited to human studies that were published in the English literature from January 1990 to April 2010. Data extraction was conducted independently by two investigators (F.B. and G.Z.S.). Inconsistent data were discussed with the other authors when necessary. Consensus was achieved for all data inclusion before metaanalysis. Duplicate reports for the same study subjects were eliminated and additional data were obtained through direct contact with investigators when necessary.
Data synthesis and analysis
The analyses were performed using Review Manager 5.0. Continuous data were expressed as the mean difference with 95% confidence interval (CI).
The mean difference of outcomes to antiviral therapy was generated using the random effects model. Heterogeneity was quantified using a chi-square test, and the quantity of heterogeneity was evaluated using I 2 statistic [24] . Sources of heterogeneity were assessed with subgroup analysis, which were performed only when data from at least two studies were available for each subgroup. Publication bias was measured by the test of funnel plot asymmetry. The 5% significance level was used for alpha risk. Every estimate was given with its 95% CI.
Studies reporting complete data on the levels of proteinuria and serum creatinine were meta-analysed. Additionally, to investigate the effect of sustained virological response (SVR) on outcomes of CKD patients with HCV infection, the studies on case series, in which all cases were HCVassociated CKD patients receiving antiviral therapy and had similar clinical features, were grouped and analysed simultaneously as a whole (named hereafter mixpaper) for increasing the patient number of SVR and non-SVR groups. Here, SVR was defined as HCV RNA negative 24 weeks after cessation of treatment and non-SVR as failure to clear HCV RNA from serum at the end of standard treatment or relapsers during follow-up.
Results
Literature review
Our electronic and manual searches identified a total of 2089 citations ( Figure 1 ). After review of titles, 1233 of these were excluded for being irrelevant to anti-HCV treatment in CKD patients. After screening by title and abstract, 797 additional citations were excluded according to protocol of eligible and ineligible studies. The remaining 59 studies were selected for full article review. By carefully examining the full texts, eleven clinical trials [7, 9, 10, 12, 19, 23, [25] [26] [27] [28] [29] were included in our metaanalysis ( Figure 1 ). There was full concordance between the two independent reviewers with respect to the final inclusion and exclusion of studies reviewed. 
Patient characteristics
Salient demographic characteristics of subjects enrolled in the included studies are shown in Tables 1-3 . Six studies were from Europe, two from the USA, two from Asia and one from Africa. Six of the selected studies were controlled clinical trials and five uncontrolled prospective studies (Table 1) . Information on a total of 225 patients was provided in the 11 studies ( Table 2) . Twelve of the 225 subjects were lost to follow-up or terminated anti-viral therapy due to side effects. The mean age of subjects ranged from 36 AE 9 to 64 AE 12 years old. The proportion of males ranged from 15.1 to 68.0%. HCV genotype was provided in seven studies (Table 2 ). Five studies were based on IFNa monotherapy and six on a combined IFNa and ribavirin regimen (Table 3) . Eight trials used conventional IFNa, while the other three used both conventional IFNa and pegylated-IFNa (pegIFNa). The duration of anti-viral treatment ranged from 24 to 96 weeks. Among the 143 subjects who were treated with anti-HCV therapy, 51 achieved SVR. Data at baseline on proteinuria and creatinine serum levels are shown in Table 2 . Some of the studies provided serum alanine aminotransferase levels, histological patterns of HCV-related glomerulonephritis and other risk factors such as hypertension, but there were insufficient data about their influence on CKD and IFN response.
Summary estimates of outcomes between pre-and posttreatment
Based on completeness of data reported, seven studies were analysed for proteinuria and six for serum creatinine evolution between baseline and after treatment using Review Manager 5.0 software (data of serum creatinine not reported in reference [19] ). Figure 2 shows the comparison of proteinuria decrease and the mean difference of outcome achieved after antiviral therapy in each study. The summary estimate for the mean difference of proteinuria decrease at the end of therapy was 2.71 g/24 h (95% CI, 1.38-4.04, P < 0.0001) according to the random effects model. Using mean difference as the measure of effect, the homogeneity test statistic yielded a P-value of 0.05, and the heterogeneity was I 2 ¼ 53%. Figure 3 shows the comparison of creatinine decrease from baseline to after treatment. The pooled mean difference of creatinine decrease at the end of therapy was 0.23 mg/dL (95% CI 0.02-0.44, P ¼ 0.03) according to the random effects model. Using mean difference as the measure of effect, the homogeneity test statistic yielded a P-value of 0.30, and the heterogeneity was I 2 ¼ 17%.
Summary estimates of outcomes between SVR and non-SVR subjects
The comparison between SVR and non-SVR groups is shown in Figures 4 and 5 . Only six studies compared proteinuria or creatinine decrease between the two groups, and, among them, four studies were case reports [10, 19, 26, 27] . These cases had similar clinical features. Therefore, their data was grouped and analysed as a whole study, and the forest plots in Figures 4 and 5 only show three studies.
According to the random effects model, the summary estimate for the mean difference of proteinuria decrease was 1.04 g/24 h (95% CI 0.20-1.89, P ¼ 0.02) in patients who achieved SVR. Using mean difference as the measure of effect, the homogeneity test statistic yielded a P-value of 0.21, and the heterogeneity was I 2 ¼ 36% (Figure 4 ). The comparison of creatinine decrease between SVR and non-SVR groups is shown in Figure 5 . The pooled mean difference of blood creatinine decrease in SVR patients was 0.05 mg/dL (95% CI, À0.33 to 0.43, P ¼ 0.80). Using mean difference as the measure of effect, the homogeneity test statistic yielded a P-value of 0.70, and the heterogeneity was I 2 ¼ 0%.
Discussion
Conventional treatment of patients with glomerulonephritis frequently includes steroids, immunosuppressive agents and sometimes plasmapheresis. For patients with HCVassociated glomerulonephritis, the preferred treatment strategy of conventional treatment alone, antiviral approach based on IFNa alone or combination therapy remains undefined [30] . Johnson et al. reported that oral steroids with HCV-associated nephritis had no beneficial effect on kidney function, although it may have improved the purpura. While pulse steroids were associated with improvement in renal function, these patients remained HCV-RNA positive [28] . One problem with steroids and immunosuppressive therapy is the increase in HCV-RNA levels with its possible detrimental consequences on the underlying liver disease [31] . Cyclophosphamide was successfully used for treatment of HCV-infected patients with cryoglobulinaemia and progressive loss of kidney function due to MPGN, but the HCV-RNA levels increased in these patients [32] . It has been suggested that in infected individuals, immunosuppressive therapy after kidney transplantation could be associated with worsening of HCV liver disease [8] .
In a prior meta-analysis of antiviral with immunosuppressive therapy for HCV-associated glomerulonephritis, it was shown that standard IFNa therapy was more effective than immunosuppressive therapy in lowering proteinuria of patients with HCV-associated glomerulonephritis, whereas serum creatinine levels were not affected by either therapy [33] . However, the studies selected in this meta-analysis included patients who received immunosuppressive agents during antiviral treatment, making it difficult to determine the actual differential effect of each treatment alone. Additionally, variable antiviral regimens including inconsistent doses and duration of treatment would be expected to have a negative impact on conclusions about the efficacy of IFNa. In order to avoid these problems, the present meta-analysis compares results before to after stable regimens of antiviral therapy in subjects with HCV-associated glomerulonephritis and compares the results of those subjects who achieved SVR to those who failed to do so (no SVR).
Despite the increased number of reported clinical studies of antiviral treatment of HCV-associated glomerulonephritis, the actual number of patients studied remains relatively small [33] . In this meta-analysis, the number of subjects in each of the 11 selected studies ranged from 3 to 53 patients In the Alric study, 18 treated patients received a two-phase treatment. Patients were treated first for nephrotic-range proteinuria with furosemide and angiotensin converting enzyme inhibitor. After 4-12 weeks, all of them received anti-HCV combination therapy. Shown here is the mean value before the primary therapy, and however, in Figure 2 , the pretreatment mean value of 1.98 for proteinuria is that before anti-HCV therapy.
c Derived from individual proteinuria values supplied in reference [30] . Treatment of HCV-associated glomerulopathy (Table 1) . In fact, when we divided the patients into SVR and non-SVR groups, the number of cases in some studies was too small for statistical analysis. Therefore, four of the case series were pooled into a 'mixpaper' for the purpose of comparing outcomes between SVR and non-SVR group [10, 19, 26, 27] . Our meta-analysis shows that antiviral treatment based on IFNa can decrease protein excretion or creatinine levels in CKD patients infected with HCV. Following antiviral treatment, protein excretion decreased significantly [mean difference, 2.71 g/24 h; (95% CI 1.38-4.04, P < 0.0001)]. Serum creatinine levels also decreased significantly [mean difference, 0.23 mg/dL; (95% CI 0.02-0.44, P ¼ 0.03)] at the end of therapy, according to the random effects model (Figures 2  and 3) . Because of reporting median data only, four studies were not included in the analysis, but they made the same conclusion that antiviral therapy helped alleviate proteinuria, which supports the result of the present meta-analysis on protein excretion decrease by IFN therapy [9, 12, 25, 29] . In addition, three of the four excluded studies stated that IFNa did not improve the creatinine levels, except for Misiani's report [9] , which may affect the pooled result of blood creatinine decrease after antiviral treatment.
The improvement in protein excretion following antiviral therapy was linked to HCV RNA clearance. Comparison between non-SVR and SVR groups demonstrated that protein excretion decreased significantly in subjects who achieved SVR [mean difference, 1.04 g/24 h; (95% CI 0.20-1.89, P ¼ 0.02)]; however, a significant decrease in blood creatinine was not observed in the SVR group [mean difference, 0.05 mg/dL (95% CI À0.33 to 0.43, P ¼ 0.80)] (Figures 4 and 5) . Fabrizi et al. [33] suggest that decreased proteinuria per se at the end of antiviral treatment can reduce or prevent the decline of glomerular filtration over time in patients with HCV-associated glomerulonephritis (GN). However, an additional mechanism whereby viral clearance improves kidney disease remains to be determined. This can be attributed to the suppression of circulating immune complexes in chronic infection and its associated B-lymphocyte cryoglobulin production both of which account for the HCV-induced glomerular injury [7, 8] .
Additionally, HCV genotypes affect responses to IFN treatment. In the seven studies, HCV genotype was determined to decide dose and duration of therapy, but there were no data about the association between HCV genotype and HCV-related glomerulonephritis or that of achieving SVR. As such, these issues cannot be addressed in this analysis but do not seem to influence the conclusion that response patterns of antiviral therapy can change levels of proteinuria and creatinine.
The treatment of choice for chronic hepatitis C (CHC) is IFNa combined with ribavirin [15] . As shown in general CHC patients [15] , ribavirin can significantly improve SVR in HCV-associated glomerulonephritis in this analysis. Among the patients with IFN plus ribavirin combination therapy achieved a higher SVR than those with IFN monotherapy (32/82 versus 10/61, v 2 ¼ 8.636, P ¼ 0.0033) regardless of HCV genotype, type of IFN and antiviral therapy duration. Alric et al. [7] observed a high rate of SVR (66.7%) with combination therapy, although half of their patients were infected with HCV genotype 1. Compared with IFN monotherapy, the major side effect of combination treatment was ribavirin-induced hemolytic anemia, which necessitated reduction of ribavirin dose or the use of erythropoietin in a few patients. No patient required discontinuation of antiviral treatment because of this.
As with most meta-analyses, there are limitations to the present study. A major one is the small number of study subjects making it difficult to perform subgroup analysis on the basis of cryoglobulinemia, baseline proteinuria, baseline creatinine level, pathological pattern of CKD, the presence of hypertension or diabetes mellitus or concomitant immunosuppressants. Another limitation is the lack of randomized controlled trials (RCTs) of IFNa-based therapy in HCV-associated GN. In addition, the included papers did not specify whether patients received concomitant therapy able to reduce proteinuria such as ACE-inhibitors or angiotensin-receptor blockers. However, the link between SVR and reduction of proteinuria in this meta-analysis supports a causal link between antiviral therapy per se and the evolution of proteinuria. Only one of the 11 studies in this analysis was an RCT [9] . Importantly, the analysed data is on outcomes achieved upon completion of therapy, whereas improvement of kidney function is a long process. Regrettably, there are no long-term follow-up studies on treated patients. Whether antiviral treatment based on IFNa can delay or reverse the progress of CKD in the long run remains unknown. Longer duration of follow-up, and kidney biopsies would be needed to adequately evaluate the outcomes. Further, larger RCTs using regular treatment with standard or pegylated IFNa on HCV-related glomerulopathy are required.
In conclusion, antiviral therapy based on IFNa can significantly decrease proteinuria in patients with HCVassociated glomerulonephritis. The improvement in protein excretion is linked to HCV RNA clearance as the treatment effect was greater in patients achieving SVR than in those without SVR. Serum creatinine levels are not significantly improved whether obtaining SVR or not, but stabilization of serum creatinine is achieved with IFNabased treatment. These results suggest that patients with HCV-associated glomerulonephritis should receive antiviral therapy with the aim of achieving SVR and alleviating CKD.
